TCR2 Therapeutics Inc. (TCRR) Stock Price Hits All-Time Low Today

The stock of TCR2 Therapeutics Inc. (NASDAQ:TCRR) reached all time low today, May, 17 and still has $12.95 target or 8.00 % below today’s $14.08 share price. This indicates more downside for the $337.07 million company. This technical setup was reported by If the $12.95 PT is reached, the company will be worth $26.97M less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only.

The stock decreased 5.06% or $0.75 during the last trading session, reaching $14.08. About 13,081 shares traded. TCR2 Therapeutics Inc. (NASDAQ:TCRR) has 0.00% since May 17, 2018 and is . It has underperformed by 4.37% the S&P500.

TCR2 Therapeutics Inc. (NASDAQ:TCRR) Ratings Coverage

Among 3 analysts covering TCR2 Therapeutics (NASDAQ:TCRR), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. TCR2 Therapeutics had 3 analyst reports since March 11, 2019 according to SRatingsIntel.

More notable recent TCR2 Therapeutics Inc. (NASDAQ:TCRR) news were published by: which released: “Stocks To Watch: Those Ticking Clocks – Seeking Alpha” on February 09, 2019, also with their article: “TCR2 Therapeutics readies IPO – Seeking Alpha” published on December 30, 2018, published: “TCR2 Therapeutics Publishes First Peer-Reviewed Data Demonstrating Superior Anti-Tumor Activity of the Company’s Novel TRuCâ„¢-T Cells – GlobeNewswire” on May 07, 2019. More interesting news about TCR2 Therapeutics Inc. (NASDAQ:TCRR) were released by: and their article: “Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems – Benzinga” published on February 28, 2019 as well as‘s news article titled: “64 Stocks Moving In Friday’s Mid-Day Session – Benzinga” with publication date: March 01, 2019.

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. The company has market cap of $337.07 million. The Company’s product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies. It currently has negative earnings. The firm was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.